These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22710900)

  • 1. Optimizing premedications in the prevention of bendamustine infusion-related reactions.
    Tombleson RL; Ho V; Sokol L; Pinilla J; Wetzstein GA
    Cancer Control; 2012 Jul; 19(3):245-7. PubMed ID: 22710900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Hoy SM
    Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
    Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
    Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.
    Becker M; Tschechne B; Reeb M; Schwinger U; Bruch HR; Frank M; Straßl L
    Ann Hematol; 2015 Sep; 94(9):1553-8. PubMed ID: 26122866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
    Ghesquières H; Stamatoullas A; Casasnovas O; Morschhauser F; Gyan E; Gabarre J; Malphettes M; Clément L; Ferlay C; Brice P
    Leuk Lymphoma; 2013 Nov; 54(11):2399-404. PubMed ID: 23410099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
    García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C
    Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
    Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
    Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.
    Fraser C; Brown P; Megason G; Ahn HS; Cho B; Kirov I; Frankel L; Aplenc R; Bensen-Kennedy D; Munteanu M; Weaver J; Harker-Murray P
    J Pediatr Hematol Oncol; 2014 May; 36(4):e212-8. PubMed ID: 24072240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
    García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
    Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
    Lissitchkov T; Arnaudov G; Peytchev D; Merkle Kh
    J Cancer Res Clin Oncol; 2006 Feb; 132(2):99-104. PubMed ID: 16292542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
    Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
    Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine: a new look at an old drug.
    Kalaycio M
    Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.
    Czuczman MS; Kahanic S; Forero A; Davis G; Munteanu M; Van Den Neste E; Offner F; Bron D; Quick D; Fowler N
    Ann Hematol; 2015 Apr; 94(4):633-41. PubMed ID: 25630297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
    Chacar C; Jabbour E; Ravandi F; Borthakur G; Kadia T; Estrov Z; Rios MB; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):197-200. PubMed ID: 22578814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ; Gregory SA
    Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
    Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.